Compare RingCentral Inc. Class A Common Stock (RNG) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
RingCentral Inc. Class A Common Stock vs Travere Therapeutics Inc. Common Stock — how do they compare? RingCentral Inc. Class A Common Stock trades at $74.8 (market cap $6.53B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: RingCentral Inc. Class A Common Stock is the larger of the two by market cap, and RingCentral Inc. Class A Common Stock pays a 0.35% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold RingCentral Inc. Class A Common Stock for 6 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| RNG | TVTX | |
|---|---|---|
Market Cap | $6.53B | $4.88B |
Volume | 1,430,504 | 1,668,577 |
Sector | Technology | Health |
52-Week High | $79.82 | $67.52 |
52-Week Low | $24.82 | $26.79 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $7.58B | $5.01B |
Dividend Yield | 0.35% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RingCentral (RNG) trades at $78.69, up 0.67% on the day and near its 52-week high, reflecting strong momentum. The stock is technically bullish with moving averages supporting the uptrend. Fundamentally, the company shows revenue growth to $2.52 billion in 2025, with net income of $43.39 million and improving margins. Recent earnings beats and strategic AI partnerships, like the one with Allnet.Italia announced October 13, 2026, underscore growth potential. Analyst sentiment is overwhelmingly positive with 28 buy ratings and a consensus price target of $61.00, though the current price exceeds this target.
The outlook for RNG is favorable driven by AI integration and earnings momentum, but risks include high valuation with a P/E of 62.54 and potential volatility ahead of Q3 2026 results on October 22, 2026. Investor focus remains on execution and margin expansion amid competitive pressures.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About RingCentral Inc. Class A Common Stock
RingCentral provides cloud-based business communications and contact center solutions. Its platform combines phone, messaging, video meetings, and customer-service tools.
Read more on RNG →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
